Popular GLP-1 Weight Loss Drugs Are Being Misused by People Struggling with Eating Disorders, Research Reveals

A recent study published in JAMA Psychiatry reveals a significant prevalence of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications usage among individuals with eating disorders, highlighting concerns of misuse. This troubling trend is particularly notable given that there are no approved medical uses for these drugs in treating eating disorders.

High Rates of GLP-1 RA Usage

Researchers from the University of Louisville conducted a study involving 436 individuals in the United States diagnosed with various eating disorders, including anorexia nervosa, bulimia nervosa, and binge eating disorder. The findings indicated that approximately 32.1% of participants reported having used GLP-1 RAs, such as Ozempic or Wegovy, at some point in their lives, a figure significantly higher than the 15% found in the general adult population. Furthermore, about 22% of these participants were still using the medications at the time of the study.

Patterns of Misuse Detected

Among the respondents, nearly 10% disclosed misusing these medications. Misuse included practices such as taking higher doses than prescribed, extending the duration of use beyond medical recommendations, or sharing the drugs with others without professional approval. Additionally, some individuals purchased compounded versions of GLP-1 drugs from unregulated sources, raising concerns about safety and efficacy.

Implications for Mental Health and Management

Eating disorders are complex conditions with severe implications for mental health, often accompanying issues such as depression and anxiety. The misuse of GLP-1 medications among these individuals could exacerbate these conditions and heighten the risks associated with their eating disorders. Given the lack of approved treatments for eating disorders involving GLP-1 drugs, researchers call for increased monitoring and further investigation into the motivations behind their use and the marketing strategies that may be influencing individuals with eating disorders.

THE CNP TAKEAWAY

While GLP-1 medications have proven effective for certain conditions, their use among individuals with eating disorders raises significant risks. Awareness and careful monitoring of these patterns are essential for ensuring safety and appropriate treatment.

Images courtesy of Shutterstock.

This article was prepared by The Center for Nutritional Psychology based on the new article entitled “Prevalence of GLP-1 RA Use and Misuse in Patients with Eating Disorders,” authored by Sanjukta Mondal. Read medicalxpress.com